Stockreport

Therapix Biosciences announces results of Phase IIa study at for Tourette syndrome program; shares ahead 35% premarket [Seeking Alpha]

THERAPIX BIOSCIENCES LTD AMERICAN DEPOSITARY SHARE  (TRPX) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/trpx
PDF Therapix Biosciences announces results of Phase IIa study at for Tourette syndrome program; shares ahead 35% premarketTherapix Biosciences (NASDAQ:TRPX) surges35% premar [Read more]